EyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships
September 11 2017 - 6:30AM
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the
“Company”), a clinical-stage specialty pharmaceutical company
focused on developing and commercializing products using two
proprietary platform technologies for treating diseases and
disorders of the eye, today announced its launch of a social media
presence on Facebook, Twitter and LinkedIn.
Because the information distributed through the
social media channels may be deemed material, investors should
follow or like the following pages in addition to monitoring
EyeGate’s website, press releases, SEC filings and other
traditional channels.
Facebook: https://www.facebook.com/EyeGatePharma/Twitter:
https://twitter.com/EyeGatePharma (@EyeGatePharma)LinkedIn:
https://www.linkedin.com/company/135892/
“Social media is an increasingly effective way
to enhance relationships within the investor and medical research
communities,” commented Stephen From, EyeGate’s President and
CEO. “Investors, development partners, employees, vendors and
all EyeGate stakeholders will benefit from greater insight into our
business that results from our posts on these pages.”
About EyeGate
EyeGate is a clinical-stage specialty
pharmaceutical company focused on developing and commercializing
products using its two proprietary platform technologies for
treating diseases and disorders of the eye. EyeGate’s most advanced
platform is based on a cross-linked thiolated carboxymethyl
hyaluronic acid (“CMHA-S”), a modified form of the natural polymer
hyaluronic acid (“HA”), which is a gel that possesses unique
physical and chemical properties such as hydrating and healing when
applied to the ocular surface. The ability of CMHA-S to adhere
longer to the ocular surface, resist degradation and protect the
ocular surface makes it well-suited for treating various ocular
surface injuries.
EGP-437, EyeGate’s other product in clinical
trials, incorporates a reformulated topically active
corticosteroid, Dexamethasone Phosphate that is delivered into the
ocular tissues through EyeGate’s proprietary innovative drug
delivery system, the EyeGate II Delivery System. For more
information, please visit www.EyeGatePharma.com.
EyeGate Social Media
EyeGate uses its website
(www.EyeGatePharma.com), Facebook page (https://www.facebook.com/
EyeGatePharma/), corporate Twitter account
(https://twitter.com/EyeGatePharma), and LinkedIn page
(https://www.linkedin.com/company/135892/) as channels of
distribution of information about EyeGate and its product
candidates. Such information may be deemed material information,
and EyeGate may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should
monitor EyeGate’s website and its social media accounts in addition
to following its press releases, SEC filings, public conference
calls, and webcasts. The social media channels that EyeGate
intends to use as a means of disclosing the information described
above may be updated from time to time as listed on EyeGate’s
investor relations website.
Forward-looking Statements
Some of the statements in this press release are
“forward-looking” and are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
These “forward-looking” statements include statements relating to,
among other things, the commercialization efforts and other
regulatory or marketing approval efforts pertaining to EyeGate’s
products, including EyeGate’s EGP-437 combination product and those
of Jade Therapeutics, Inc., a wholly owned subsidiary of EyeGate,
as well as the success thereof, with such approvals or success may
not be obtained or achieved on a timely basis or at all. These
statements involve risks and uncertainties that may cause results
to differ materially from the statements set forth in this press
release, plus other risk factors described under the heading “Risk
Factors” contained in EyeGate’s Annual Report on Form 10-K filed
with the SEC on February 23, 2017 or described in EyeGate’s other
public filings. EyeGate’s results may also be affected by factors
of which EyeGate is not currently aware. The forward-looking
statements in this press release speak only as of the date of this
press release. EyeGate expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to such
statements to reflect any change in its expectations with regard
thereto or any changes in the events, conditions or circumstances
on which any such statement is based.
Contact:
Lee Roth / Janhavi MohiteThe Ruth Group for
EyeGate Pharmaceuticals646-536-7012 /
7026lroth@theruthgroup.com /
jmohite@theruthgroup.com
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Aug 2024 to Sep 2024
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Sep 2023 to Sep 2024